Edwards Lifesciences Corporation (EW)

Market Cap	42.10B
Revenue (ttm)	5.44B
Net Income (ttm)	4.17B
Shares Out	587.90M
EPS (ttm)	6.97
PE Ratio	10.28
Forward PE	29.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	448,484
Open	71.24
Previous Close	72.05
Day's Range	71.00 - 72.34
52-Week Range	58.93 - 95.25
Beta	1.15
Analysts	Buy
Price Target	79.95 (+11.65%)
Earnings Date	Apr 24, 2025

About EW

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 27, 2000
• Employees: 15,800
• Stock Exchange: NYSE
• Ticker Symbol: EW
• Website: https://www.edwards.com

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.

Analyst Forecast

According to 21 analysts, the average rating for EW stock is "Buy." The 12-month stock price forecast is $79.95, which is an increase of 11.65% from the latest price.

Price Target

$79.95

(11.65% upside)

Analyst Consensus: Buy